Cyclerion Therapeutics announced an exclusive strategic collaboration with Medsteer, a leader in anesthetic delivery systems driven by real-time patient feedback. The new collaboration is intended to enable the integration of Medsteer’s proprietary technology and know-how into Cyclerion’s lead program, CYC-126, a potentially novel anesthetic-based investigational therapy currently being developed for the treatment of treatment-resistant depression (TRD).
CYC-126 is being designed as an individualized, precision-delivered treatment that leverages well-characterized anesthetic agents in combination with real-time EEG monitoring and algorithm-guided dosing. Cyclerion believes this approach has the potential to enable clinicians to more precisely guide patients toward targeted brain states that may be associated with antidepressant effects, addressing a significant unmet need among patients with TRD. Regina Graul, Chief Executive Officer of Cyclerion, said, “This strategic collaboration with Medsteer marks an important step in advancing our lead program, CYC-126, a potential first-in-class therapy for treatment-resistant depression. Medsteer’s deep translational expertise and proven closed-loop anesthetic delivery technology make them an ideal strategic partner to accelerate our anesthesia-enabled platform development while potentially reducing technical and execution risk.”
Medsteer’s Technology and Clinical Validation
Medsteer’s EasyTIVA regulation algorithm has been clinically validated through more than 25 clinical settings and more than 9,000 patients. The proprietary solution automates the delivery of propofol and remifentanil using AI-based algorithms. Nicolas Choussat, co-founder and Chief Operating Officer of Medsteer, stated, “Integrating intelligent software agents with real-time patient feedback holds great potential to improve clinical outcomes. We are thrilled to ramp up our work with Cyclerion Therapeutics in the field of neuropsychiatry and leverage our proprietary algorithms to help build the next generation of therapies.”
Development Timeline and Regulatory Path
Following the strategic development collaboration announcement, Cyclerion remains on track to complete device integration and finalize its proprietary drug delivery system ahead of the planned initiation of the Phase 2 proof-of-concept study of CYC-126 in the second half of 2026. The Company expects to leverage FDA-cleared device components, together with the Medsteer strategic partnership and a previously announced MIT license, with Cyclerion’s own fit-for-purpose improvements, to support full device build prior to Phase 2 start.
Cyclerion is advancing its regulatory strategy to initiate a multinational Phase 2 proof-of-concept clinical trial. The Company currently plans to target first patient enrollment in Australia in 2026 under the CTN/HREC (Clinical Trial Notification / Human Research Ethics Committee) pathway, while continuing preparatory work to support a potential future U.S. IND submission. Initial proof-of-concept clinical data from this program are currently expected in 2027.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110558839/Cyclerion-Therapeutics-Announces-Strategic-Agreement-With-Medsteer-And-Progress-Toward-Initiating-Phase-2-Proof-Of-Concept-Study-For-CYC-126-In-Treatment-Resistant-Depression